|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Securities held to maturity, at amortized cost ($113,700 and $105,146 fair value at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Securities available for sale, at fair value ($506,871 and $171,796 amortized cost at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses - loans ("ACL-Loans") | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Cash value of life insurance | ||||||||||||||||||||
| Core deposit intangibles, net | ||||||||||||||||||||
| Mortgage servicing rights ("MSR") | ||||||||||||||||||||
| Other real estate owned ("OREO") | ||||||||||||||||||||
| Investment in Ansay and Associates, LLC ("Ansay") | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Noninterest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Securities sold under repurchase agreements | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Subordinated notes | ||||||||||||||||||||
| Junior subordinated debenture | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Common stock - $0.01 par value; Authorized - 20,000,000 shares; Issued - 12,898,070 and 11,515,130 shares as of June 30, 2026 and December 31, 2025, respectively; Outstanding - 11,079,310 and 9,834,623 shares as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost - 1,818,760 and 1,680,507 shares as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
